news
Discovery could lead to targeted melanoma therapies
18 June 2015 | By Victoria White
Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a new study...
List view / Grid view
Melanoma
news
Anisina confirmed as effective anti-cancer agent in preclinical studies
14 May 2015 | By Victoria White
Novogen has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model...
news
Significant progress made towards individualised cancer immunotherapy
12 May 2015 | By Victoria White
Mainz-based researchers have made significant advances with regard to the development of individualised cancer immunotherapy strategies...
news
Studies confirm TRXE-009 kills resistant paediatric brain cancer cells
11 May 2015 | By Victoria White
Novogen, in conjunction with Australian paediatric cancer researchers, released key preclinical data on experimental cancer drug-candidate, TRXE-009...
news
Plexxikon and MSD team up to evaluate PLX3397 in combination with KEYTRUDA
7 May 2015 | By Victoria White
Plexxikon and MSD have announced a collaborative clinical trial that will evaluate the combination of PLX3397 and KEYTRUDA in melanoma...
news
ROCK inhibitors could stop the spread of melanoma cells
6 May 2015 | By Victoria White
Scientists at The Institute of Cancer Research have found that ROCK inhibitors dramatically reduced the ability of melanoma cells to move through tissue...
news
New research describes blueprint for truly personalised cancer immunotherapies
23 April 2015 | By Victoria White
An article describing an important scientific foundation for the clinical development of truly personalised cancer immunotherapies has been published...
news
Novogen and the Feinstein Institute collaborate to develop effective treatments for brain cancers
17 April 2015 | By Victoria White
Novogen and the Feinstein Institute for Medical Research are to collaborate to develop effective treatments for brain cancers...
news
New study reveals Anisina kills melanoma cells regardless of their mutation status
9 April 2015 | By Victoria White
Novogen has announced that studies conducted at UQDI revealed that experimental drug Anisina killed melanoma cells irrespective of their mutational status...
news
Consortium signs deal with Basilea to develop resistance-busting cancer drugs
1 April 2015 | By Victoria White
A consortium will collaborate with Basilea to progress a new family of cancer drugs designed to block several key cancer-causing proteins at once...
news
First treatment approved under EAMS developed using antibody humanization expertise at UK’s MRC Technology
11 March 2015 | By MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma...
news
Launch of the anti-cancer agent / BRAF inhibitor “Zelboraf”
26 February 2015 | By Roche
Contribution to the treatment of melanoma by personalized healthcare...
news
Trial finds cancer drug can block key signal in cancer growth and drug resistance
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
news
New targeted drugs could treat drug-resistant skin cancer
15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...
news
Bristol-Myers Squibb and Five Prime Therapeutics to evaluate combination of Opdivo (nivolumab) and FPA008 in six tumor types
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...
